A Phase 3 study evaluating mitapivat for pediatric participants with pyruvate kinase deficiency (PKD) who are not regularly transfused has completed its primary period on 2024-12-13. This milestone indicates the conclusion of the main data collection phase for the trial.

Background

The study focuses on mitapivat, also known as Pyrukynd or Aqvesme, in the context of pediatric pyruvate kinase deficiency (PKD). PKD is a rare, inherited metabolic disorder that affects red blood cells, leading to chronic hemolytic anemia. The trial specifically addresses pediatric patients who do not require regular blood transfusions, aiming to assess the drug's efficacy and safety in this particular subgroup.

Trial design

The Phase 3 study, identified as NCT05175105 (ACTIVATE-Kids), enrolled 30 participants. The trial's objective is to evaluate the efficacy and safety of orally administered mitapivat compared with a placebo in pediatric participants with pyruvate kinase deficiency (PKD) who are not regularly receiving blood transfusions. Participants were randomized 2:1 to receive either mitapivat or mitapivat-matching placebo. Randomization was stratified by age, including groups of 1 to < 6 years, 6 to < 12 years, and 12 to < 18 years. The double-blind period included an 8-week dose titration period followed by a 12-week fixed-dose period. The primary outcomes for this study were not specified in the provided data.

What this means

The primary completion of the Phase 3 ACTIVATE-Kids study signifies that the main treatment and data collection period has concluded for mitapivat in pediatric patients with pyruvate kinase deficiency (PKD) who are not regularly transfused. While this marks a significant step in the trial's progression, specific efficacy and safety results are not yet available. The completion of this phase means that researchers will now proceed with data analysis, and the findings will be crucial for understanding the potential role of mitapivat as a treatment option for this vulnerable pediatric population. The study is followed by a 5-year extension period, indicating a long-term follow-up for participants.

Source

Information regarding the primary completion of this trial was obtained from ClinicalTrials.gov, a public database of clinical studies. The update for study NCT05175105, titled "A Study to Evaluate the Efficacy and Safety of Mitapivat in Pediatric Participants With Pyruvate Kinase Deficiency (PKD) Who Are Not Regularly Transfused, Followed by a 5-Year Extension Period", was posted on 2024-12-13 on clinicaltrials.gov.